Overview

Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, with the improvement of living standards and changes in lifestyle and dietary habits, non-alcoholic fatty liver disease (NAFLD) has become another important cause of liver cirrhosis and HCC.HBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis, which greatly increases the risk of cirrhosis, liver cancer and even end-stage liver disease. We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation, fibrosis in patients with CHB associated NAFLD. In addition, to find risk factors for liver cirrhosis, liver cancer or liver failure in patients with CHB-related NAFLD.

Eligibility

Inclusion Criteria:

        1.18 years or older 2. Positive hepatitis B surface antigen (HBsAg) for at least 6 months
        and without other viral co-infection at baseline 2.NAFLD diagnosed by imaging liver biopsy,
        and/or blood testing/predictive indices
        Exclusion Criteria:
          1. Other chronic liver diseases, such as alcoholic liver disease, other viral hepatitis,
             drug-induced liver injury;
          2. HCC or other malignancies before liver biopsy;